Research Analysts Issue Forecasts for PHIO FY2025 Earnings

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) – Research analysts at HC Wainwright upped their FY2025 earnings per share estimates for shares of Phio Pharmaceuticals in a research note issued to investors on Tuesday, April 8th. HC Wainwright analyst V. Bernardino now forecasts that the company will post earnings of $4.30 per share for the year, up from their prior estimate of $3.76. HC Wainwright currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for Phio Pharmaceuticals’ current full-year earnings is ($8.54) per share.

Phio Pharmaceuticals Price Performance

Shares of Phio Pharmaceuticals stock opened at $1.74 on Thursday. Phio Pharmaceuticals has a one year low of $0.97 and a one year high of $9.79. The business’s 50 day simple moving average is $1.46 and its two-hundred day simple moving average is $2.26. The stock has a market capitalization of $8.31 million, a P/E ratio of -0.16 and a beta of 1.09.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in shares of Phio Pharmaceuticals Corp. (NASDAQ:PHIO) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned 0.59% of Phio Pharmaceuticals as of its most recent SEC filing. Institutional investors and hedge funds own 57.31% of the company’s stock.

Phio Pharmaceuticals Company Profile

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.